Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi, Daiichi Sankyo, Mitsubishi Tanabe Await Subsidiary Action For Results: Japanese Earnings Roundup (Part 2 Of 2)

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Offering a mixed bag of earnings results, Shionogi, Daiichi Sankyo, and Mitsubishi Tanabe all await action of some sort by subsidiaries to determine their FY2010 outcomes. For Shionogi, that means a need for a U.S. rebound from its Sciele subsdiary, Daiichi Sankyo is holding out for the results of Ranbaxy, and Mitsubishi Tanabe is eyeing the impact of its subsidiary-induced sales suspension. [Editor's note: Part 1 of the Japanese earnings roundup with Astellas and Eisai appeared yesterday (PharmAsia New, Aug. 3, 2010).]
Advertisement

Related Content

Astellas, Eisai Tout Pipeline Updates In Face Of Patent Losses: Japanese Earnings Roundup (Part 1 Of 2)
Astellas, Eisai Tout Pipeline Updates In Face Of Patent Losses: Japanese Earnings Roundup (Part 1 Of 2)
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
FDA Approval Obtained, Other Hurdles Remain For Daiichi's Tribenzor
ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III
Daiichi Sankyo's Factor Xa Bests Enoxaparin In Phase III Trial For VTE
MHLW Suspends Mitsubishi Tanabe Operations For Fabricating Data
As Crestor Patent Trial Nears, Generic Firms Seek To Block AstraZeneca Subsidiary From Suit
Advertisement
UsernamePublicRestriction

Register

SC075807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel